Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,000)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06455124 | Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE) | recruiting | Phase 2 | 60 | Fudan UniversityOTHER | 1 | Jun 13, 2024 | clinicaltrials |
| NCT06451211 | Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer(Neo-ICEBOAT) | recruiting | Phase 2 | 53 | Sun Yat-sen UniversityOTHER | 1 | Jun 11, 2024 |
| NCT04891016 | Toripalimab Plus FLOT in Locally Advanced Gastric Cancer | recruiting | Phase 2 | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Jun 6, 2024 | clinicaltrials |
| NCT06429839 | Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients | recruiting | Phase 2 | 55 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT06427460 | Central-boost Ablative Radiation Therapy for Solid Tumors (CBART) | recruiting | Phase 2 | 67 | Changhai HospitalOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT06423170 | A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs | recruiting | Phase 2 | 37 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT06410651 | Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 53 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT06406634 | Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma | recruiting | Phase 2 | 30 | Hunan Cancer HospitalOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06397222 | Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC | recruiting | Phase 2 | 23 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT06389422 | Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis | recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 29, 2024 | clinicaltrials |
| NCT05228431 | Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer | recruiting | Phase 2 | 121 | Zhen-Hai LuOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT06360042 | Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC | recruiting | Phase 2 | 111 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT06296563 | Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC | recruiting | Phase 2 | 20 | Lei ZHAOOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06363825 | A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 57 | Fujian Medical UniversityOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06371586 | Neo-Sequence 2：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC | recruiting | Phase 2 | 67 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06111274 | A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer | recruiting | Phase 2 | 82 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06354218 | Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age | recruiting | Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06354530 | A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 / Phase 3 | 266 | Army Medical Center of PLAOTHER_GOV | 1 | Apr 9, 2024 | clinicaltrials |
| NCT05984810 | NIR-Fluorescence Guided Surgical Resection of Neoadjuvant Treated Localized Pancreatic Cancer Using SGM-101(FLUOPANC-II) | recruiting | Phase 2 | 20 | Leiden University Medical CenterOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT05652920 | Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC | recruiting | Phase 1 / Phase 2 | 105 | OriCell Therapeutics Co., Ltd.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06221748 | DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy | recruiting | Phase 2 / Phase 3 | 90 | RemeGen Co., Ltd.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06202001 | Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients | recruiting | Phase 1 / Phase 2 | 70 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06341595 | Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM | recruiting | Phase 2 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04660760 | Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer | recruiting | Phase 2 | 116 | Academic and Community Cancer Research UnitedOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06145074 | Examining Safety, Efficacy and Feasibility of Preoperative Propranolol in Patients With PDAC.(IMPULS) | recruiting | Phase 2 | 30 | Zealand University HospitalOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06196788 | Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer(PTCA199-9) | recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06265025 | GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 125 | GeneMedicine Co., Ltd.INDUSTRY | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06234007 | Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study | recruiting | Phase 2 | 45 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT06304350 | Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 25 | Tongji UniversityOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT05975749 | Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer | recruiting | Phase 2 | 114 | Fudan UniversityOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06187597 | Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)(EC-CRT-007) | recruiting | Phase 2 | 140 | Sun Yat-sen UniversityOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06261125 | Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)(HSBRT2401) | recruiting | Phase 2 | 60 | Mian XIOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06293014 | TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer | recruiting | Phase 2 | 224 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 5, 2024 | clinicaltrials |
| NCT05970666 | Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma | recruiting | Phase 2 | 71 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06151262 | A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer | recruiting | Phase 2 | 30 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT06228963 | Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma | recruiting | Phase 2 | 160 | Fudan UniversityOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT06270017 | Evaluation of Metastatic Disease and Oncological Treatment in Patients With Colon Cancer Using Zebra Fish Avatars(ZEBRA-COLON) | recruiting | Phase 1 / Phase 2 | 300 | University Hospital, LinkoepingOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT06266832 | The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma | recruiting | Phase 2 | 30 | Sir Run Run Shaw HospitalOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT05007132 | Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer | recruiting | Phase 2 | 153 | Dominik Paul ModestOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT05988814 | Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy(FOLFIRINOX3 P) | recruiting | Phase 2 | 90 | Centre Georges Francois LeclercOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT06254521 | The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer | recruiting | Phase 2 | 60 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT05678270 | A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 70 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06245330 | A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Ascentawits Pharmaceuticals, LtdINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT02215889 | Partial Liver Segment 2/3 Transplantation Study | recruiting | Phase 1 / Phase 2 | 20 | Oslo University HospitalOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06244225 | HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma | recruiting | Phase 2 | 38 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06242067 | Second-line Treatment of Metastatic Colorectal Cancer(BEV-TASIRI) | recruiting | Phase 2 | 50 | Qilu Hospital of Shandong UniversityOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT06229340 | Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations(NТО-RAS) | recruiting | Phase 2 | 20 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | Jan 29, 2024 | clinicaltrials |
| NCT06218810 | Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer | recruiting | Phase 2 | 53 | Fudan UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06205472 | Phase II Study of Adjuvant SIB Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC. | recruiting | Phase 2 | 100 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT05245474 | Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer | recruiting | Phase 2 | 186 | Beijing Friendship HospitalOTHER | 1 | Jan 10, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jun 13, 2024source: clinicaltrials